National Institute for Health and Care Excellence

**Brain tumours (primary) and brain metastases in adults**

**Consultation on draft quality standard – deadline for comments** 5pm on 06/09/21

**Please email your completed form to**:QSconsultations@nice.org.uk

Please read the checklist for submitting comments at the end of this form. We cannot accept forms that are not filled in correctly.

Use the form to comment on the content of the quality standard (i.e. the statements and other sections e.g. rationale, measures etc.), as well as answer the following questions:

1. Does this draft quality standard accurately reflect the key areas for quality improvement?
2. Are local systems and structures in place to collect data for the proposed quality measures? If not, how feasible would it be for these to be put in place?
3. Do you think each of the statements in this draft quality standard would be achievable by local services given the net resources needed to deliver them? Please describe any resource requirements that you think would be necessary for any statement.
4. For draft quality statement 4: Is it feasible to carry out an assessment and discussion about the risk of late effects of treatment at the first follow-up appointment after treatment? If not, please say why and if possible, suggest an alternative timescale.
5. For draft quality statement 5: Stakeholders have highlighted the need to improve access to neurological rehabilitation for adults with brain tumours. Do we have the right focus for this statement? If not, please identify the key action needed for improvement.

# Organisation details

|  |  |
| --- | --- |
| **Organisation name**  (if you are responding as an individual rather than a registered stakeholder please leave blank) |  |
| **Disclosure**  Please disclose any past or current, direct or indirect links to, or funding from, the tobacco industry. |  |
| **Name of person completing form** |  |
| **Supporting the quality standard**  Would your organisation like to express an interest in formally supporting this quality standard? [More information.](https://www.nice.org.uk/standards-and-indicators/get-involved/support-a-quality-standard) |  |
| **Type** | **[Office use only]** |

# Comments on the draft quality standard

|  |  |  |
| --- | --- | --- |
| **Comment number** | Statement or question number  Or ‘general’ for comments on the whole document | Comments Insert each comment in a new row.  Do not paste other tables into this table because your comments could get lost – type directly into this table. |
| *Example 1* | *Statement 1* | *This statement may be hard to measure because…* |
| 1 | General |  |
| 2 | Question 1 |  |
| 3 | Question 2 |  |
| 4 | Question 3 |  |
| 5 | Question 4 |  |
| 6 | Question 5 |  |
| 7 | Statement 1 |  |
| 8 | Statement 2 |  |
| 9 | Statement 3 |  |
| 10 | Statement 4 |  |
| 11 | Statement 5 |  |
|  |  |  |

# Insert more rows as needed

# Checklist for submitting comments

* Use this form and submit it as a Word document (not a PDF).
* Complete the disclosure about links with, or funding from, the tobacco industry.
* Combine all comments from your organisation into 1 response. We cannot accept more than 1 response from each organisation.
* Do not paste other tables into this table – type directly into the table.
* **Clearly mark any confidential information or other material that you do not wish to be made public. Also, ensure you state in your email to NICE that your submission includes confidential comments.**
* Do not include medical information about yourself or another person from which you or the person could be identified.
* Spell out any abbreviations you use

Please return to [QSconsultations@nice.org.uk](mailto:QSconsultations@nice.org.uk)

NICE reserves the right to summarise and edit comments received during consultations, or not to publish them at all, where in the reasonable opinion of NICE, the comments are voluminous, publication would be unlawful or publication would be otherwise inappropriate.

Comments received from registered stakeholders and respondents during our stakeholder engagements are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the comments we received, and are not endorsed by NICE, its officers or advisory Committees.